8-K Impact 9/10 Regulatory / Fda

$SMMT · Summit Therapeutics Inc.

November 16, 2026 · AI-analyzed SEC filing · Verify material figures against the official SEC.gov filing

Summit Therapeutics disclosed on November 15, 2026 that the FDA issued a Complete Response Letter for the ivonescimab BLA in EGFR-mutant NSCLC. The FDA determined substantial evidence of effectiveness is not established without a statistically significant OS improvement. The HARMONi Phase III trial met its PFS primary endpoint but OS showed only a positive trend, with a post-hoc hazard ratio of 0.76.

  • FDA CRL rejects ivonescimab BLA for EGFR-mutant NSCLC after prior EGFR TKI therapy.
  • FDA: PFS benefit without statistically significant OS does not support positive benefit-risk profile.
  • HARMONi met PFS primary endpoint but OS showed only a positive trend, not statistical significance.
  • Post-hoc analysis showed OS hazard ratio of 0.76 in full, Asian, and western populations.
  • Summit continues five Phase III programs and multiple collaborations for ivonescimab in other indications.

Extended-hours last trade $11.53, down 18.52% vs regular close of $14.15, reflecting the CRL's rejection of the lead U.S. approval path.

The FDA rejection of Summit's lead U.S. filing removes a near-term catalyst and pressures the $11.29B market cap on a single-asset story.

The CRL underscores FDA's insistence on OS benefit in EGFR-mutant NSCLC, a high bar no approved regimen has met in this setting.

The CRL blocks near-term U.S. commercialization of ivonescimab in this indication and raises uncertainty about the broader development program's regulatory prospects.

Get filings like this before the market reacts.

Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.

Start your free trial →